Please check your internet connection and try again.
# Brexanolone
## Overview
Brexanolone is a neuroactive steroid GABA-A receptor modulator indicated for the treatment of postpartum depression (PPD).
## Primary Indications
Treatment of moderate to severe postpartum depression (PPD) in adults.
## Adult Dosing
Administered as a continuous intravenous (IV) infusion.
* **Day 1:** Initiate at 0.5 mcg/kg/min for 4 hours. Then, increase to 1 mcg/kg/min for 20 hours.
* **Day 2:** Administer at 1 mcg/kg/min for 24 hours.
* **Day 3:** If tolerated, increase to 1.5 mcg/kg/min for 24 hours.
* **Day 4:** If tolerated, increase to 2 mcg/kg/min for 24 hours.
**Maximum dose:** 90 mcg/kg/min.
**Duration of infusion:** Typically 60 hours.
## Pediatric Dosing
No established pediatric dosing.
## Dose Adjustments
* **Excessive Sedation:** Decrease infusion rate.
* **Over-sedation/Syncope:** Discontinue infusion.
* **Renal Impairment:** No specific dose adjustment recommended, but caution is advised.
* **Hepatic Impairment:** No specific dose adjustment recommended, but caution is advised.
## Contraindications
* Hypersensitivity to brexanolone or any of its components.
## Adverse Effects
* **Most Common:** Sedation, somnolence, dizziness, dry mouth, fatigue, headache, feeling hot, rash, decreased oxygen saturation, and hypoesthesia.
* **Serious:** Excessive sedation and syncope.
## Key Drug Interactions
* **CNS Depressants:** Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, alcohol) may increase the risk of sedation and respiratory depression. Monitor closely.
* **CYP3A4 Inhibitors/Inducers:** Brexanolone is a substrate of CYP3A4. Concurrent use of strong CYP3A4 inhibitors or inducers may alter brexanolone plasma concentrations.
## Monitoring
* **Level of Consciousness and Sedation:** Continuous monitoring is required during infusion. Use a standardized sedation scale (e.g., RASS).
* **Oxygen Saturation:** Continuous pulse oximetry.
* **Vital Signs:** Blood pressure, heart rate.
* **Patient Reported Symptoms:** Assess for PPD symptoms throughout and after treatment.
## Clinical Pearls
* Brexanolone is administered in a healthcare setting with continuous monitoring due to the risk of excessive sedation and syncope.
* Patients must not drive or operate heavy machinery until at least 24 hours after the infusion is completed and they are no longer experiencing sedation.
* The total duration of infusion may be adjusted based on patient response and tolerability.
***
**Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and local protocols for complete details and to verify all drug information before use.
